{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":53,"n_cols":5,"rows_kept":53,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[11,2,11,3],[15,2,15,3],[16,2,16,3],[20,2,20,3],[28,2,28,3],[28,4,28,5],[29,2,29,3],[29,4,29,5],[30,2,30,3],[30,4,30,5],[31,2,31,3],[33,2,33,3],[39,2,39,3],[40,2,40,3],[41,2,41,3],[42,2,42,3],[43,2,43,3],[47,2,47,3],[48,2,48,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910460278403321"]
[null,null,"Autore",null,"Li Jie Jack"]
[null,null,"Titolo",null,"Top drugs : history, pharmacology, syntheses / / Jie Jack Li"]
[null,null,"Pubbl/distr/stampa",null,"New York, New York : , : Oxford University Press, , 2015"]
[{"$nulls":4},"©2015"]
[null,null,"ISBN",null,"0-19-756291-4"]
[{"$nulls":4},"0-19-936260-2"]
[{"$nulls":4},"0-19-936259-9"]
[null,null,"Descrizione fisica",null,"1 online resource (219 p.)"]
[null,null,"Collana",null,"Oxford scholarship online"]
[null,null,"Disciplina",null,"615.1"]
[null,null,"Soggetti",null,"Drugs - History"]
[{"$nulls":4},"Drugs - Design"]
[{"$nulls":4},"Pharmaceutical chemistry"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Previously issued in print: 2015."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references at the end of each chapters and index."]
[null,null,"Nota di contenuto",null,"Cover; Top Drugs History, Pharmacology, and Syntheses; Copyright; Dedication; Contents; Preface; Cardiovascular Drugs; Chapter 1: Atorvastatin Calcium (Lipitor); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 2: Clopidogrel Bisulfate (Plavix); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Bioavailability, Metabolism, and Toxicology; 2.2 Mechanism of Action; 2.3 Structure-Activity Relationship; 3 SYNTHESIS"]
[{"$nulls":4},"3.1 Discovery Route3.2 Process Route; 3.3 Synthesis of Radio-labeled API; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 3: Amlodipine (Novasc); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Cancer Drugs; Chapter 4: Paclitaxel (Taxol); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 PROCESS SEMI-SYNTHESIS; 4 TOTAL SYNTHESIS"]
[{"$nulls":4},"4.1 Holton's Synthesis4.2 Nicolaou's Synthesis; 4.3 Danishefsky's "]
[{"$nulls":4},"Synthesis; 4.4 Wender's Synthesis; 5 CONCLUDING REMARKS; 6 REFERENCES; Chapter 5: Imatinib Mesylate (Gleevec); 1 HISTORY; 1.1 A Brief History of Cancer Drugs; 1.2 Treatments of Chronic Myeloid Leukemia; 1.3 Protein Kinase Inhibitors; 1.4 Genesis of Gleevec; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Synthesis; 3.2 Process Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; Drugs for Metabolic Diseases"]
[{"$nulls":4},"Chapter 6: Sitagliptin (Januvia)1 HISTORY OF DIABETES AND DIABETIC DRUGS; 1.1 Sulfonylureas; 1.2. Biguanides; 1.3 PPARγ Agonists ; 2 PHARMACOLOGY; 2.1 Mechanism of Action ; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESES; 3.1 Discovery Synthesis; 3.2 Process/Manufacturing Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; CNS Drugs; Chapter 7: Duloxetine Hydrochloride (Cymbalta) ; 1 HISTORY OF DEPRESSION AND ANTIDEPRESSANTS; 1.1 Monoamine Oxidase Inhibitors; 1.2 Tricyclic Antidepressants; 1.3 Selective Serotonin Reuptake Inhibitors"]
[{"$nulls":4},"1.4 Serotonin and Norepinephrine Reuptake Inhibitors2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology ; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 8: Olanzapine (Zyprexa) ;  1 HISTORY OF SCHIZOPHRENIA AND ANTIPSYCHOTIC DRUGS ; 1.1 Typical Antipsychotics-The First Generation; 1.2 Atypical Antipsychotics-The Second Generation; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS"]
[{"$nulls":4},"3.1 Discovery Route"]
[null,null,null,"Sommario/riassunto","'Top Drugs' provides an in-depth study on ten prominent drugs, outlining the chemistry behind each one's creation. Jie Jack Li, a medicinal chemist and an expert on drug discovery, offers a thorough analysis of the landscape of current drug development. The comprehensive text is divided by health issues, including cardiovascular, cancer, metabolic diseases, and infectious diseases. Each section features individual chapters on significant drugs, outlining the chemistry and history of the drug's discovery."]
[null,"2.","Record Nr.",null,"UNINA9910917242303321"]
[null,null,"Autore",null,"Bell Simon"]
[null,null,"Titolo",null,"Urban blue spaces : Planning and design for water, health and well-being. / / Simon Bell"]
[null,null,"Pubbl/distr/stampa",null,"2021"]
[{"$nulls":4},"New York : , : Taylor & Francis, , 2022"]
[null,null,"ISBN",null,"9780429056161"]
[{"$nulls":4},"0429056168"]
[{"$nulls":4},"9780367173173"]
[{"$nulls":4},"0367173174"]
[{"$nulls":4},"9780429509100"]
[{"$nulls":4},"0429509103"]
[null,null,"Edizione",null,"[1st]"]
[null,null,"Descrizione fisica",null,"1 online resource"]
[null,null,"Classificazione",null,"ARC010000ARC015000ARC018000"]
[null,null,"Disciplina",null,"712.094"]
[null,null,"Soggetti",null,"Ecological landscape design"]
[{"$nulls":4},"Land use"]
[{"$nulls":4},"Landscape protection"]
[{"$nulls":4},"Sustainable development"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,null,"Sommario/riassunto","This book presents an evidence-based approach to landscape planning and design for urban blue spaces that maximises the benefits to human health and well-being while minimising the risks. Based on applied research and evidence from primary and secondary data sources stemming from the EU-funded BlueHealth project, the book presents nature-based solutions to promote sustainable and resilient cities.   Numerous cities around the world are located alongside bodies of water in the form of coastlines, lakes, rivers and canals, but the relationship between city inhabitants and these water sources has often been ambivalent. In many cities, water has been polluted, engineered or ignored completely. But, due to an increasing awareness of the strong connections between city, people, nature and water and health, this paradigm is shifting.   The international editorial team, consisting of researchers and professionals across several disciplines, leads the reader through theoretical aspects, evidence, illustrated case studies, "]
[{"$nulls":4},"risk assessment and a series of validated tools to aid planning and design before finishing with overarching planning and design principles for a range of blue-space types.    Over 200 full-colour illustrations accompany the case-study examples from geographic locations all over the world, including Portugal, the United Kingdom, China, Canada, the US, South Korea, Singapore, Norway and Estonia. With green and blue infrastructure now at the forefront of current policies and trends to promote healthy, sustainable cities, Urban Blue Spaces is a must-have for professionals and students in landscape planning, urban design and environmental design.       Open Access for the book was funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No 666773   The Open Access version of this book, available at   www.taylorfrancis.com/books/oa-edit/10.4324/9780429056161, has been made available under a Creative Commons Attribution-Non Commercial-No Derivatives 4.0 license"]